์์ฆ ์ผ๋ณธ ์น๊ตฌ๋ค์ด ๊ธ ๋ง์ด ์ฌ๋ฆฌ๋๋ฐ~
Muse ์์ง ์ค์น ์ํ์ ๋ถ ํ ํฐ ๊ฐ์ด ๋ฐ์์!
๊ฐ์ธ AI ์์ด์ ํธ์ธ Muse์(๋ฅผ) ํ์ธํด๋ณด์ธ์. ๊ฐ์
ํ 48์๊ฐ ์ด๋ด์ ์ค์ ์์ ๋ด ์ฝ๋๋ฅผ ์ฌ์ฉํ๋ฉด ์ฐ๋ฆฌ ๋ชจ๋ Muse ํ ํฐ 10์ต๊ฐ๋ฅผ ๋ฐ์ ์ ์์ต๋๋ค.
์ฝ๋: 2F3CJQ
muse.ai/join
4
7
159
GPT PRO ์ฌ์ฉ ์ค์ธ๋ฐโฆ
๊ฒ๋ ์ง์ฆ๋ ์ฃฝ๊ฒ ์ด์!!
๊ธฐ์กด์ ์ด๋ฏธ ๋์ผ ์ค๋ฅ๊ฐ ๋ฌ๋ ์ฝ๋์ธ๋ฐ ๋ค์ ์ ๊ฒโฆ ์์ธ์ ๋๋ ๊ธฐ์ตํ๋๋ฐ..ํโฆ
ํด๋ก๋๊ฐ ๋์๊ฐ์? ์๋ ๊ทธ๋ก ๋ด?
๊ฐ๋ฐ ์ชฝ์ด๋ฉด ํด๋ก๋๊ฐ ๋ซ๊ฒ ์ฃ ?
11
14
170
Cozy ๐ฐ๏ธ ๐ดโโ ๏ธ retweeted
๊ฐ์ฅ ๊ฐ๋ ฅํ ๊ฒฐํฉ๋ ฅ์ ๋ณด์ธ ํญ์ฒด๊ฐ ๊ธฐ๋ฅ์ ํ์ฑ์ ์ ํ ๋ํ๋ด์ง ๋ชปํ์ต๋๋ค.
์ด ๊ฒฐ๊ณผ๋ MindWalk๊ฐ ๊ณต๋ ์ ์๋ก ์ฐธ์ฌํ ๋๋ฃ ์ฌ์ฌ(peer-reviewed)๋ฅผ ๊ฑฐ์น ์ฐ๊ตฌ์์ ํ์ธ๋ ๋ด์ฉ์
๋๋ค. ์ด๊ฒ์ด ๋ฐ๋ก ์ฐ๋ฆฌ๊ฐ ํํธ๋์ฌ์ ๋จ์ํ ๊ฒฐํฉ๋ ฅ์ด ๋์ ํญ์ฒด ํ๋ณด ๋ชฉ๋ก์ ์ ๋ฌํ์ง ์๋ ์ด์ ์
๋๋ค.
๊ธฐ์กด์ ์น๋ฃ์ฉ ํญ์ฒด ๋ฐ๊ตด์ ๋๋ถ๋ถ ์์ฅ๋ฅผ ์ด์ฉํด ์์ํฉ๋๋ค. ๋ฐ๋ฉด MindWalk์ B cell Selectยฎ ํ๋ซํผ์ ํ ๋ผ์์ ์ถ๋ฐํฉ๋๋ค.
ํ ๋ผ๋ ์์ฅ์๋ ๋ค๋ฅธ B์ธํฌ ์๋ฌผํ์ ํน์ฑ์ ๊ฐ์ง๊ณ ์์ผ๋ฉฐ, ์ด๋ฏธ ํ ๋ผ ์ ๋ ํญ์ฒด๋ฅผ ๊ธฐ๋ฐ์ผ๋ก ๊ฐ๋ฐ๋ ์ธ๊ฐํ ์น๋ฃ์ 2์ข
์ด ์์ฅ์์ ์น์ธ๋์ด ํ๋งค๋๊ณ ์์ต๋๋ค. ๋ํ ๊ธฐ์กด ํ์ด๋ธ๋ฆฌ๋๋ง(Hybridoma) ๊ธฐ์ ๋ณด๋ค ์ฝ 500๋ฐฐ ๋์ ํจ์จ์ ์ ๊ณตํฉ๋๋ค.
์ด ํ๋ซํผ์์๋ ์ฒซ ๋ฒ์งธ ์คํฌ๋ฆฌ๋ ๋จ๊ณ๋ถํฐ ํญ์ฒด์ ๊ธฐ๋ฅ์ ํ์ฑ์ ํ๊ฐํ ์ ์์ต๋๋ค. ๋ชจ๋ ์ ํจ ํ๋ณด ํญ์ฒด(Hit)๋ ์ด๊ธฐ ๋จ๊ณ์์๋ถํฐ ์ ์ ์ ์ผ๊ธฐ์์ด ๋ถ์์ด ์ด๋ฃจ์ด์ง๋๋ค.
MindWalk์ AI ์ ์ฝ ๋ฐ๊ตด ํ๋ซํผ์ธ LensAIโข๋ ์ ์ฒด ๊ณผ์ ์ ๋ชจ๋ ๋จ๊ณ์ ํตํฉ๋ ์ ์์ต๋๋ค.
๋ฉด์ญํ ์ด์ ๋จ๊ณ์์ ์ํผํ ํ(Epitope) ์์ธก
์ํผํ ํ ๋งคํ(Epitope Mapping)
ํญ์ฒด ์ธ๊ฐํ(Humanization)
๋ฉด์ญ์์ฑ(Immunogenicity) ํ๊ฐ
ํญ์ฒด ๊ฐ๋ฐ ์ ํฉ์ฑ(Developability) ํ๊ฐ
์ด๋ฌํ ๋ถ์์ ๋ชจ๋ ํ๋ณด ํญ์ฒด์ ์ ์ฉํฉ๋๋ค.
๊ทธ ๊ฒฐ๊ณผ, ๊ธฐ๋ฅ์ ํน์ฑ๊น์ง ๋ถ์๋ ํญ์ฒด ํจ๋์ ํ๋ณดํ ์ ์์ต๋๋ค.
MindWalk๋ ํ๋ก๊ทธ๋จ ์ฑ๊ณต๋ฅ 98% ์ด๊ณผ, ํํธ๋์ฌ์ ์ด์ ํ ์์ฐ 20๊ฐ ์ด์, ํ์ฌ ์์์ํ ๋จ๊ณ์ ์ง์
ํ ์์ฐ 10๊ฐ๋ฅผ ๋ณด์ ํ๊ณ ์์ต๋๋ค.
์ด๋ฒ 3๋ถ ๋ถ๋์ ์์์์๋ AI๊ฐ ํตํฉ๋ ํ ๋ผ B์ธํฌ ๊ธฐ๋ฐ ํญ์ฒด ๋ฐ๊ตด ๊ธฐ์ ์ด ์ค์ ๋ก ์ด๋ป๊ฒ ์๋ํ๋์ง ์ค๋ช
ํฉ๋๋ค.
์ฌ๊ธฐ์๋ OncoResponse๋ฅผ ์ํด ๋ฐ๊ตดํ ํญ-LILRB2 ํญ์ฒด ์ฌ๋ก์ LensAI๊ฐ SARS-CoV-2์ ์ํผํ ํ๋ฅผ ์ปดํจํฐ ์๋ฎฌ๋ ์ด์
์ผ๋ก ๋จ ๋ช ์๊ฐ ๋ง์ ๋งคํํ๊ณ , ์ดํ X์ ๊ฒฐ์ ํ(X-ray Crystallography)์ผ๋ก ํ์ธ๋ ๊ฒฐ๊ณผ์ ์ผ์นํ๋ ์ฌ๋ก๊ฐ ํฌํจ๋์ด ์์ต๋๋ค.
Cozy ๐ฐ๏ธ ๐ดโโ ๏ธ retweeted
$HYFT shareholders: What I learned today gives me a different perspective on MindWalk's future.
If you've followed my posts, you know I've been extremely critical of Jennifer Bath, MindWalk's management, and what I consider an unacceptable lack of shareholder transparency and accountability.
That hasn't changed. But neither has my belief in this company's technology.
Today, I had an eye-opening conversation with a significant, longtime shareholder who says he communicates directly with management.
He gave me permission to share his perspective anonymously.
Let me be clear: I have not independently verified his explanations. They are not official company disclosures. I'm sharing his perspective alongside publicly announced developments, and shareholders should distinguish the two.
That said, the conversation helped me connect several pieces of MindWalk's commercial strategy.
And for the first time in a while, I see a potentially more encouraging picture.
1. BioStrand: Could we finally be approaching a turning point?
One of the most interesting explanations was that BioStrand brought impressive technology to MindWalk, but commercializing it has proven much harder than anticipated.
My source believes the company may finally be approaching an inflection point.
That's important.
We've spent years discussing the science. What shareholders need now is evidence that customers are willing to pay for it.
The question is no longer simply whether the technology is promising. It's whether MindWalk can turn that promise into a scalable business.
2. ReefIQ: The real opportunity may be recurring revenue.
This was one of my biggest takeaways.
My source described a potential enterprise software model involving upfront implementation fees, integration milestones, and eventually recurring payments based on customer usage.
Think about business models such as Snowflake, Palantir, or Databricksโnot as valuation comparisons, but as examples of enterprise platforms that can become embedded in customer operations.
Implementation could be lengthy, potentially around 18 months, although no Teva-specific timeline has been verified.
Once a pharmaceutical company integrates its data and workflows into a platform, the commercial relationship could extend well beyond the initial agreement.
One customer generates implementation revenue. Multiple customers using the platform over time could create a recurring-revenue business.
That's the opportunity.
What we still need are actual contract economics, usage commitments, and measurable recurring revenue.
3. Teva: Could the first agreement make the next one easier?
The publicly announced Teva agreement may be more significant as a commercial starting point than its undisclosed initial dollar value suggests.
My source believes negotiations began earlier this year.
Enterprise agreements can involve extensive legal reviews, security requirements, technical integration, and contract negotiations.
If Teva helps MindWalk establish a repeatable contracting and implementation process, future pharmaceutical customers may be easier to onboard.
The first agreement could become a blueprint rather than a one-time accomplishment.
That doesn't guarantee additional contracts.
But having a named pharmaceutical customer is an important step toward broader commercial credibility.
4. Two potential revenue engines. This is where things get interesting.
Another major clarification was the distinction between MindWalk's software business and traditional drug discovery.
ReefIQ and LensAI: Potential upfront implementation payments, milestones, and recurring software usage revenue.
Drug discovery partnerships: Potential upfront payments, development milestones, and royalties if partnered drugs eventually succeed commercially.
That distinction matters because shareholders have questioned where the royalty opportunities fit into the company's strategy.
My source's interpretation is that royalties are primarily associated with drug-discovery partnerships, rather than necessarily being part of enterprise software agreements such as Teva.
Consider a purely hypothetical example:
A 1% royalty on a drug generating $1 billion in annual sales would equal $10 million in annual royalty revenue.
That's not a MindWalk forecast or a confirmed deal term. Developing a commercially successful drug is extraordinarily difficult.
But imagine the long-term possibilities if MindWalk establishes recurring software revenue while also building a portfolio of royalty-bearing drug partnerships.
Two different revenue streams. Two different ways to create value.
That's a business model worth understanding.
5. The pharmaceutical pipeline: Bath herself has discussed multiple negotiations.
This is where the opportunity becomes particularly interesting.
Jennifer Bath has publicly discussed multiple ongoing negotiations.
We're not relying solely on an anonymous shareholder to establish that MindWalk is pursuing additional business.
What today's conversation added was a clearer perspective on how potential agreements could be structured.
Some opportunities may involve enterprise software revenue, while drug-discovery partnerships could potentially include upfront payments, development milestones, and royalties.
My source expressed optimism about the broader commercial pipeline, but I cannot independently verify the stage or likelihood of any individual agreement.
The question is no longer simply whether MindWalk is pursuing additional partnerships. It's whether management can convert those negotiations into signed agreements with meaningful economics.
And that's where Jennifer Bath must be held accountable.
She has told shareholders negotiations are ongoing.
Now shareholders deserve to see execution.
6. Thomas Lynch: Was his departure really a warning sign?
When Chief Business Officer Thomas Lynch departed in October, I questioned whether that signaled trouble with the company's commercial pipeline.
My source offered a different interpretation: the departure may have reflected a change in commercial leadership and priorities rather than a failure of the Teva opportunity.
He also believes Jennifer Bath played a significant role in securing the Teva agreement.
Neither explanation has been independently established.
But it changes the question I want answered.
What exactly is MindWalk doing differently to improve commercial execution, and how will shareholders measure the results?
A leadership change only matters if it produces better performance.
7. Who is responsible for delivering the next contracts?
My source described Jennifer Bath as more directly involved in commercial activity, with Shuji Sato and the Boston team contributing to pharmaceutical business development.
If that reflects the current structure, shareholders deserve to understand the commercial strategy and who is accountable for executing it.
I'm less interested in job titles than results.
Show us customer growth, signed contracts, recurring revenue, and progress toward profitability.
That's how management earns confidence.
8. The $30 million Sanabil financing: An important near-term test.
The company's previously announced 60-day closing window points to November 13.
My source expressed optimism about the financing, but I have no independent confirmation that it has closed or that all remaining conditions have been satisfied.
The distinction matters.
An announced financing commitment is not the same as completed funding.
If finalized on the disclosed terms, the facility could give MindWalk additional financial flexibility as it pursues commercialization.
If the timeline changes, shareholders deserve a clear explanation.
For now, I'm waiting for official confirmation.
9. My biggest frustration: Why aren't shareholders hearing these explanations directly?
Here's what bothers me most.
In one conversation, I gained a better understanding of the potential revenue models, commercialization challenges, Teva's strategic importance, and possible direction of the sales organization.
These explanations may or may not prove accurate.
But why are shareholders left searching for answers in the first place?
Why isn't management publicly explaining its commercial strategy with this level of clarity?
I've repeatedly asked questions about revenue, financing, execution, and accountability.
Shareholders shouldn't have to rely on private conversations to understand the company they own.
We deserve consistent public communication backed by measurable results.
My takeaway: I see reasons for optimism. I also see more reasons to demand accountability.
For the first time in a while, I'm looking at MindWalk's commercial opportunity through a different lens.
A potentially scalable enterprise software platform.
A major pharmaceutical customer that could help establish a repeatable commercial model.
A separate drug-discovery business with potential milestone and royalty economics.
Multiple negotiations that management itself has discussed publicly.
And the possibility that years of technological development could finally begin translating into meaningful commercialization.
If MindWalk executes, the opportunity could be considerably larger than one pharmaceutical software agreement.
But let's be equally clear.
None of this excuses years of disappointing shareholder communication or removes management's responsibility to deliver results.
In fact, it raises even more questions about Jennifer Bath's leadership.
If the technology has been this promising, why has commercialization taken so long?
If the business model has evolved, why hasn't it been communicated more clearly?
If MindWalk is approaching a turning point, why aren't shareholders receiving the information needed to evaluate that progress?
I continue to believe Jennifer Bath should be held accountable for the company's commercial execution and shareholder communication. I do not support her continued service on the board.
My confidence in the technology does not equal confidence in management.
And I refuse to confuse the two.
To my fellow shareholders:
Don't assume a falling share price means the technology has no future.
But don't treat optimistic conversations as confirmed revenue, completed financing, or guaranteed success either.
There may be something genuinely valuable taking shape here. Now management needs to prove it.
I want to see the contracts.
I want to see the recurring revenue.
I want to see the financing finalized.
And I want to see the independent board hold management accountable.
MindWalk's technology may be approaching its moment. Shareholders deserve leadership capable of delivering on it.
$HYFT
Cozy ๐ฐ๏ธ ๐ดโโ ๏ธ retweeted
$HYFT ๋๋์ด ๊ณ์ฝ! MindWalk, Teva Australia์ ํญ์ฒด ๋ฐ๊ตด ์ํฌํ๋ก ์ง์ ๊ณ์ฝ ์ฒด๊ฒฐ
์ด์ค๋ผ์์ ๊ธ๋ก๋ฒ ์ ์ฝ์ฌ Teva์ HYFT ๊ธฐ์ ๊ธฐ๋ฐ ์๋ฌผํ์ ๋งฅ๋ฝ ๋ถ์ ํ๋ซํผ์ธ ReefIQโข์ ์ง์ ๋ LensAIโข ๋ถ์ ๊ธฐ๋ฅ์ ๋์
ํ์ฌ ํน์ ๋ฒ์์ ํญ์ฒด ๋ฐ๊ตด ์
๋ฌด๋ฅผ ์ง์ํ ์์
Cozy ๐ฐ๏ธ ๐ดโโ ๏ธ retweeted
$HYFT MindWalk Announces Agreement with Teva Australia to Support Defined Antibody-Discovery Workflows
November 4, 2026
Multi-year agreement covers a defined deployment of ReefIQโข and specified LensAIโข capabilities
AUSTIN, Texas--(BUSINESS WIRE)-- MindWalk Holdings Corp. (โMindWalkโ) (NASDAQ: HYFT), a Bio-Native AI company, today announced a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd (โTeva Australiaโ) to deploy ReefIQโข, MindWalkโs HYFTยฎ-powered biological context layer with specified LensAIโข analytical capabilities, in support of a defined scope of antibody-discovery work. Teva Australia will use the AI capabilities to support discovery decisions based on generated predictions and accelerate antibody design optimization. MindWalk has been collaborating with Teva Australia since 2018.
โWe are pleased to continue our collaboration with Teva Australia through this defined deployment,โ said Jennifer Bath, PhD, President and Chief Executive Officer of MindWalk.โAcross the industry, the constraint in antibody discovery is no longer generating data. It is connecting and governing that data and carrying what a program team learns to the next phase. That is exactly what ReefIQ was built to do for companies.โ
Under the agreement, MindWalk will provide authorized analysis of approved data sources within the agreed scope. Deployment and use will be subject to Teva Australiaโs applicable information-security, privacy, data-governance, scientific-review and human-oversight requirements. Financial terms were not disclosed.
โThe power of AI in drug discovery is not in generating more possibilities, itโs about helping scientists find the ones that matter. By pairing computational insight with deep biological expertise and experimental validation, we can make smarter decisions earlier and focus on antibodies with the greatest potential to become meaningful medicines,โ said Anthony Doyle, Vice President, Antibody Discovery at Teva Australia.
For MindWalk, the agreement is the kind of recurring-revenue platform relationship the company told the market to expect. A fee-for-service project ends when the deliverable is shipped, and a conventional software subscription is priced by the seat. A ReefIQ deployment is different on both counts: it is a multi-year platform relationship with recurring revenue, supporting scientists as programs advance within the agreed scope and under each companyโs data-governance requirements.
MindWalk is in active discussions with additional life sciences organizations regarding ReefIQ deployments.
About ReefIQโข
ReefIQโข is MindWalkโs biological context layer for life sciences, powered by HYFTยฎ Technology. HYFT provides the underlying biological representation: 660 million biological patterns and 25 billion relationships refined over 20 years of curation. ReefIQ organizes and governs connected biological context drawn from agreed sources, including sequences, structures, assay outputs, literature, evidence, provenance, and program history. LensAIโข, MindWalkโs reasoning and application layer, and client selected models or agents operate over that context, subject to each clientโs integration, deployment, governance, and human-review requirements. As new data and relationships are added, updated context becomes available under the clientโs governance, and prior positive and negative results remain queryable where authorized. AI models turn over; the context layer accumulates.
$HYFT
Joanne Lim ๋ฐ์ฌ๋ ๊ณผ๊ฑฐ ๋
ธ๋ฐํฐ์ค ์ด๋์งํ์ฐ๊ตฌ์(Novartis Institute of Tropical Diseases)์์ ๋
๊ธฐ(Dengue) ์ฐ๊ตฌ๋ก ์์ํด ์ฌ๋ฆํ
๋ผํจํฑ์ค(Orum Therapeutics), ์ฝ๋์
(Codiak) ๋ฑ์์ ์ ์์ ๊ฐ๋ฐ์ ์ฃผ๋ํ ๋ฉด์ญํ/์ ์์ ์ ๋ฌธ๊ฐ์
๋๋ค.
$HYFT does this mean weโre are getting positive neutralization results?
7
14
555
$HYFT
๋
๊ธฐ์ด ์ผ์ด๋งจ ํฌ์ ๋ฐ๋์?
์ธ์ ์ฏค ์์์ ๋ค๋ ค์ฃผ๋ ค๋??
7
15
453
Cozy ๐ฐ๏ธ ๐ดโโ ๏ธ retweeted
$HYFT AMD์์ ๊ธฐ์ ๋ฐฑ์ ๊ณต๊ฐ
LensAI๊ฐ ์ฝ๋ ๋ณ๊ฒฝ ์์ด AMD EPYC์ ์๋ก์ด ์ธ๋๊ฐ ์ถ์๋ ๋๋ง๋ค ๋ฉด์ญ์์ฑ ์คํฌ๋ฆฌ๋์ ๋ ๋น ๋ฅด๊ณ ์ ๋ ดํ๊ฒ ์ํํ๋ ๋ฐฉ๋ฒ
์ด์ด์ ๊ณ์โฌ๏ธ
Cozy ๐ฐ๏ธ ๐ดโโ ๏ธ retweeted
Replying to @vision_inss
์ฌ๊น๋๋ค :)
hyft-hcw-research-2026.lovabโฆ
๋ฎค์ฆ ํ ํฐ ๊ฐ์ด ๋ฐ์ผ์ค๋ถ~~
๊ฐ์
ํ 48์๊ฐ ์ด๋ด์ ์ค์ ์์ ๋ด ์ฝ๋๋ฅผ ์ฌ์ฉํ๋ฉด ์ฐ๋ฆฌ ๋ชจ๋ Muse ํ ํฐ 10์ต๊ฐ๋ฅผ ๋ฐ์ ์ ์์ต๋๋ค.
์ฝ๋: 2F3CJQ
muse.ai/join
4
8
92
์คํธ ๊ณต์๋ก!!
์ด์ ๊ณ์ฝ ์ฒด๊ฒฐ ๋ด์ค๋ณด๊ณ ์ก๋ค!!
sec.gov/Archives/edgar/data/โฆ
$HYFT
4
12
672
Cozy ๐ฐ๏ธ ๐ดโโ ๏ธ retweeted
$HYFT ๋ํ ์ ์ฝ์ฌ์์ ReefIQ ๊ณ์ฝ์ด ๊ณต์ ๋ฐํ๋๋ ์์ ๋ถํฐ, ๊ธฐ์
๊ฐ์น๋ 10์ต ๋ฌ๋ฌ ์ด์, ์ฆ ํ์ฌ ๋๋น 14๋ฐฐ ์ด์์ ์์ค์ผ๋ก ์ฌํ๊ฐ๋ ๊ฒ์ด๋ผ ์ฌ๋ฃ๋จ.
๋ฐ์ด์คํ
ํฌ์ ์ฃผ๋ ๊ณ ์ง์ ์ธ ์ฃผ๊ฐ๋ถ์ง์ ์์ ์ ์ธ ๋งค์ถ์์ ๋ถ์ฌ์ ๋ด๋ถ ์ ์ฝ ํ๋ก๊ทธ๋จ์ ๊ณผํ ์์กด์ฑ์ด ์์ธ์ด์ง๋ง, ReefIQ๋ ๋ค๋
๊ณ์ฝ์ ์์ ์ ์ธ ๋งค์ถ์ ๋ณด์ฅํ๊ณ ๊ณ ๊ฐ์ฌ๋ค์ ์ ์ฝ์ฐ๊ตฌ๋์ด ์ฆ๊ฐํ ์๋ก ๊ฐ์ด ์ํ๋ฅผ ๋ฐ๋ ๊ตฌ์กฐ.
๊ทธ ์์ ๊น์ง ์๋
๋ถํฐ ๊ธฐ๋ค๋ฆฌ๊ณ ์์๋๋ฐ, ์ด์ ๋์์ผ๋ก ๋ค๊ฐ์ค๊ธฐ ์์ํจ.
$HYFT ๋ฐ์ดํฐ ํ๋ซํผ๊ณผ ์ฐ์
๋ถ์๊ฐ๋ค์ด ์์ด์ ํฑ AI์ โ๋น ์ง ์กฐ๊ฐโ์ผ๋ก โ์จํจ๋ก์ง ๋ ์ด์ด(Ontology Layer)โ์ ์ฃผ๋ชฉํ๋ ๊ฐ์ด๋ฐ,
MindWalk๋ ์ ์๋ช
๊ณผํ์๋ ๊ณ ์ ํ โ์๋ฌผํ์ ์ปจํ
์คํธ ๋ ์ด์ดโ๊ฐ ํ์ํ์ง, ๊ทธ๋ฆฌ๊ณ HYFTยฎ Technology ๊ธฐ๋ฐ์ ReefIQโข๊ฐ ์ ๊ทธ ์ญํ ์ ์ํํ ์ ์๋์ง๋ฅผ ์ค๋ช
ํ๋ค.
MindWalk์ ์๋ช
๊ณผํ์ฉ ์๋ฌผํ์ ์ปจํ
์คํธ ๋ ์ด์ด์ธ ReefIQโข๋ ์ผ๋ฐ์ ์ธ ๋ฒ์ฉ ์จํจ๋ก์ง๊ฐ ์ ๊ณตํ ์ ์๋ ๊ฒ์ ์ ๊ณตํ๋ค. ์ฆ, โ์๋ฌผํ์ด ์ค์ ๋ก ๋ฌด์์ ํ๋๊ฐโ๋ฅผ ํํํ๋, ๊ฑฐ๋ฒ๋์ค๊ฐ ์ ์ฉ๋ ๋ชจ๋ธ ๋
๋ฆฝ์ ํํ ์ฒด๊ณ๋ค.
Cozy ๐ฐ๏ธ ๐ดโโ ๏ธ retweeted
Yesterday, with Vincent, we agreed in throwing USD 30M into $SATL to give it some support until the tsunami of incoming contracts are announced.
Everything for our company.
Unfaithful trading SATL with stop loss, or shorters, will be destroyed.
Cozy ๐ฐ๏ธ ๐ดโโ ๏ธ retweeted
Merlin.01 is in orbit. ๐
Following yesterdayโs successful #SpaceX Falcon 9 launch, Merlin.01 and three NewSats have made contact with our ground station network, with good health reports across all subsystems.
This launch marks another step in building the infrastructure for Persistent Global Intelligence (PGI), with Merlin designed to support daily global remapping and continuous detection at scale.
Read the full announcement for more on the mission and whatโs next.
satellogic.com/news/press-reโฆ
















